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Heart failure is one of the key causes of morbidity and mortality world-wide. The recent findings that regeneration
is possible in the heart have made stem cell therapeutics the Holy Grail of modern cardiovascular medicine. The
success of cardiac regenerative therapies hinges on the combination of an effective allogeneic “off the shelf” cell
product with a practical delivery system. In 2007 Medistem discovered the Endometrial Regenerative Cell (ERC), a
new mesenchymal-like stem cell. Medistem and subsequently independent groups have demonstrated that ERC are
superior to bone marrow mesenchymal stem cells (MSC), the most widely used stem cell source in development.
ERC possess robust expansion capability (one donor can generate 20,000 patients doses), key growth factor
production and high levels of angiogenic activity. ERC have been published in the peer reviewed literature to be
significantly more effect at treating animal models of heart failure (Hida et al. Stem Cells 2008).
Current methods of delivering stem cells into the heart suffer several limitations in addition to poor delivery
efficiency. Surgical methods are highly invasive, and the classical catheter based techniques are limited by need for
sophisticated cardiac mapping systems and risk of myocardial perforation. Medistem together with Dr. Amit Patel
Director of Clinical Regenerative Medicine at University of Utah have developed a novel minimally invasive delivery
method that has been demonstrated safe and effective for delivery of stem cells (Tuma et al. J Transl Med 2012).
Medistem is evaluating the combination of ERC, together with our retrograde delivery procedure in a 60 heart
failure patient, double blind, placebo controlled phase II trial. To date 17 patients have been dosed and preliminary
analysis by the Data Safety Monitoring Board has allowed for trial continuation.
The combined use of a novel “off the shelf” cell together with a minimally invasive 30 minute delivery method
provides a potentially paradigm-shifting approach to cardiac regenerative therapy.Introduction
Cell-based approaches to heart failure are grounded in
the concept that regeneration is mediated by the admin-
istered cells themselves and/or that the cells act as pro-
ducers of trophic factors which stimulate cardiac
reparative processes such as angiogenesis and expansion
of endogenous cardiac specific stem cells [1,2].
In 2001, clinical use of cell therapy in cardiac disease
was reported by three independent groups using autolo-
gous myoblast [3] and bone marrow mononuclear cells
[4,5]. The promising results of these pilot studies led to
formal trials, which demonstrated statistically significant,
albeit small, improvements in cardiac function. For* Correspondence: Thomas.ichim@medisteminc.com
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reproduction in any medium, provided the orexample, a meta-analysis of 4 randomized controlled stud-
ies [6-9] and 2 cohort studies [10,11] evaluating autolo-
gous bone marrow cells administered transepicardially
during coronary artery bypass graft (CABG) revealed a
5.4% increase in left ventricular ejection fraction (LVEF) in
a total of 179 patients [12]. Bone marrow cells adminis-
tered via the intracoronary route were analyzed in 8 clin-
ical trials in post-infarct patients [13-22]. A meta-analysis
of the cumulative 725 patients revealed increased LVEF by
4.37% and reduction in left ventricular end-diastolic vol-
ume (LVEDV) by 5.71 mL, left ventricular end-systolic
volume (LVESV) by 8.94 mL, and infarct size by 2.42%,
which were all statistically significant [23].
Bone marrow mesenchymal stem cells (MSC) have
also been developed as a cell source for regenerative car-
diology. One advantage of MSC based approaches is thatl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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across different HLA haplotypes. This allogeneic ap-
proach is favored from a commercialization perspective
in that cells from a single donor may be used to produce
banks of cells that may be frozen and distributed to the
point of care. Bone marrow MSC have demonstrated
therapeutic effects in post infarct patients subsequent to
intravenous administration, thus increasing practicality
of the approach. In a 53 patient trial, the global symp-
tom score in all MSC treated patients and ejection frac-
tion was significantly improved as compared to placebo.
Additionally MSC treatment, but not placebo, increased
left ventricular ejection fraction and led to reverse re-
modeling [24]. Another study compared bone marrow
mononuclear cells with allogeneic bone marrow MSC in
30 patients with ischemic cardiomyopathy. At one year
endpoint adverse events were similar between the two
groups, with a mild increase in ejection fraction [25].
The possibility of using MSC-based therapies for heart
failure is enticing. MSC have the ability to directly differ-
entiate into cardiomyocytes [26,27], as well as to secrete
angiogeneic and trophic factors [28-30], which assist in
regeneration and possibly activation of endogenous
cardiac stem cells [31]. MSC appear to be immune
privileged and immune modulatory. Specifically, they are
poor stimulators of allogeneic immunity and in many
cases have been shown to actively inhibit ongoing im-
mune responses [32,33].
Besides the practical applications of MSC being cap-
able of transport and storage at the site of care in the
same manner that a drug would be, MSC may be stan-
dardized and optimized for specific cytokine/regenera-
tive activities. This is useful in that autologous cells from
patients with underlying conditions appear to function
sub-optimally as compared to age-matched control cells.
For example, it has been demonstrated that angiogenic
potency of bone marrow from patients with coronary ar-
tery disease is impaired, in part due to deficiencies in the
CXCR4 migration activity [34].
Endometrial regenerative cells: a novel type of MSC
The endometrium is a unique tissue in that it undergoes
approximately 500 cycles of highly vascularized growth
and regression within a tightly controlled manner in the
lifetime of the average female. This has triggered the
concept that a self-renewing cell capable of differentiat-
ing into various tissues may be present in the endomet-
rium. The possibility of a regenerative cell type resident
in the endometrium was proposed by Prianishnikov in
1978, who reported that three types of proliferative cells
exist: estradiol-sensitive cells, estradiol- and progesterone-
sensitive cells and progesterone-sensitive cells [35]. Inter-
estingly, a study in 1982 demonstrated that cells in the
endometrium destined to generate the decidual portion ofthe placenta are bone marrow derived [36], which
prompted the speculation of a stem cell-like cell in the
endometrium. Further hinting at the possibility of stem
cells in the endometrium were studies demonstrating ex-
pression of the immortality associated gene telomerase in
endometrial tissue collected during the proliferative phase
[37,38]. One study demonstrated that telomerase expres-
sion was upregulated by estradiol and FGF-2, however this
was restricted to epithelial cells of the endometrium [39].
Expression of stem cell markers such as c-kit and the
pluripotency marker Oct-4 was reported in proliferating
“label retaining” cells of the endometrium, thus further
supporting the concept that stem cells exist in this com-
partment [40].
One of the first reports of proliferative cells from the
endometrium identified clonogenic cells capable of gen-
erating stromal and epithelial cell colonies, however no
differentiation into other tissues was reported [41,42].
The phenotype of these cells was found to be CD90
positive and CD146 positive [43]. The cells isolated by
this group appear to be related to maintaining structural
aspects of the endometrium but to date have not dem-
onstrated therapeutic potential.
The first demonstration of therapeutically-relevant
stem cells derived from the endometrium occurred al-
most simultaneously by two independent groups. The
Medistem group [44], used the process of cloning rap-
idly proliferating adherent cells derived from menstrual
blood and generated a homogenous cell population
expressing CD9, CD29, CD41a, CD44, CD59, CD73,
CD90, and CD105 and lacking CD14, CD34, CD45 and
STRO-1 expression. The authors demonstrated the cells
had substantially faster replicative potential as compared
to bone marrow MSC, a unique cytokine and MMP pro-
file, as well as ability to differentiate into cardiomyocytic,
respiratory epithelial, neurocytic, myocytic, endothelial,
pancreatic, hepatic, adipocytic, and osteogenic lineages.
Interestingly, the cells identified expressed telomerase
and OCT-4 but lacked expression of NANOG-1. Given
the pluripotent nature of these cells, the authors named
them “Endometrial Regenerative Cells” (ERC). Shortly
after, Patel et al. [45] reported a population of cells
isolated using c-kit selection of menstrual blood mono-
nuclear cells. The cells had a similar phenotype, prolifer-
ative capacity, and ability to be expanded for over 68
doublings without accumulation of karyotypic abnormal-
ities. Interestingly, both groups found expression of the
pluripotency gene OCT-4 but not NANOG.
Therapeutic efficacy of ERC
Given the high degree of angiogenesis occurring
monthly in the endometrium, it is tempting to speculate
that ERC possess a physiological role in this process.
This is supported by the high concentrations of
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pared to other MSC types [44]. The therapeutic angio-
genesis promoting cytokine, VEGF, is naturally found in
the endometrium and its production is stimulated
monthly by estradiol [46]. Further supporting a role for
ovary-derived hormones in endometrial vasculogenesis
were studies in which ovarectomy resulted in lack of
VEGF production [47] and angiogenesis [48]. While the
cellular mechanisms of angiogenesis appear to be multi-
factorial and involve neutrophils [49,50], uterine NK
cells [51], and circulating endothelial progenitor cells
[52-54], the possibility of ERC playing a significant role
in this process may be considered.
To assess the role that ERC play in angiogenesis,
Murphy et al. create an aggressive murine hindlimb is-
chemia model comprising of femoral artery ligation with
nerve excision. ERC administration was capable of redu-
cing limb loss in all treated animals, whereas control an-
imals suffered limb necrosis [55]. Given that the ERC
were of human origin and the treated animals were im-
mune competent (BALB/c), it is tempting to speculate
that the cells possess a high level of immune privilege. This
was supported by experiments demonstrating inhibition of
ongoing mixed lymphocyte reaction, stimulation of the
anti-inflammatory cytokine IL-4 and suppression of in-
flammatory cytokine (IFN-g and TNF-alpha) production.
The relationship between angiogenesis and post myo-
cardial infarct healing is well-known. Given previous
work by Umezawa’s group demonstrating myocytic
differentiation of ERC-like cells [56], administration of
ERC into a model of post infarct cardiac injury was
performed [57]. Recovery was compared to bone mar-
row MSC. A superior rate of post-infarct recovery of
ejection fraction, as well as reduction in fibrosis was ob-
served with the ERC-like cells. Furthermore, the cells
were capable of functionally integrating with existing
cardiomyocytes and exerted effects through direct differ-
entiation. The investigators also demonstrated in vitro
generation of cardiomyocytes from ERC.
The stimulation of neurogenesis in post-stroke injury
models has been demonstrated to be linked directly to
angiogenesis [58]. Borlongan et al. [59], injected ERC in-
tracerebrally, or intravenously into immune competent
rats subsequent to middle cerebral artery ligation. They
demonstrated substantial increases in functional recov-
ery of the rats receiving ERC. Additionally, it was shown
that ERC secreted significant amounts of neurotrophic
growth factors including VEGF, BDNF, and NT-3.
A recent study from David Stroncek’s group at the
NIH compared gene expression profiles between bone
marrow MSC and ERC generated from 6 donors [60].
Angiogenic cytokines PDGF-BB and angiopoietin were
expressed at 27-fold and 14-fold higher levels in the
ERC compared to bone marrow MSC, respectively.Furthermore, matrix metalloprotease-3 was expressed at
29-fold higher levels in ERC. These data provide con-
firmation of previously published results in which pro-
tein levels of these factors were found to be higher in
ERC compared to bone marrow MSC and cord blood
MSC [44]. Of note, in the NIH study, significantly higher
expression of the stem cell potency-associated gene alde-
hyde dehydrogenase (39 fold), as well as immune modu-
latory genes such as pregnancy associated glycoprotein 1
(30 fold), neuronal pentatraxin (15 fold), GM-CSF (5
fold) and DAF (3 fold) was observed. The heightened ex-
pression of immune modulatory genes by ERC as com-
pared to bone marrow MSC is supported by enhanced
ability to inhibit mixed lymphocyte reaction [60].
Preclinical and clinical safety of ERC
From a safety perspective, one original concern was the
development of ectopic endometriosis. Recent studies
have demonstrated that the cells capable of producing
endometrosis-like masses in NOD-SCID mice are of the
fibroblast lineage and do not appear to be related to
ERC. To address this potential concern Medistem
performed acute (14 day) and chronic (90 day) toxicity/
tumorigenicity studies of human ERC in male and fe-
male immunocompromised mice. Cells were prepared
according to the protocol for clinical supply. Groups of
mice (both sexes) received a single unilateral intramus-
cular (IM) injection into the gastrocnemius muscle.
Agents tested included a control article (saline vehicle),
a positive control fibrosarcoma cell line and a low,
medium and high dose of ERC (3 × 104, 1 × 105, and 2 ×
105, respectively).
Observations were made throughout the study. Body
weights were measured at intervals in the study. Organ
weights and blood chemistry/hematology were measured
at the time of necropsy. Also at necropsy, gross patholo-
gies were noted and tissues were collected for histo-
pathological analysis. No early deaths occurred in the
ERC-treated or control groups. All animals in the posi-
tive control groups receiving IM injections of the fibro-
sarcoma cell line HT1080 developed tumors by 3 weeks
and either died (1 mouse) or were sacrificed because of
excessive tumor pathology. No toxicological trends or
biologically significant differences, including body weight,
were observed and values were in the normal range of his-
toric data. Histopathological examination of the injection
site revealed no abnormalities. Therefore, based on these
data, a single intramuscular injection of ERC at doses
bracketing the intended clinical dose appear to be safe and
well tolerated in immunocompromised mice.
Due to the highly angiogenic nature of ERC, one po-
tential concern would be the possibility of stimulating
progression of dormant tumors. Accordingly, Medistem
performed a series of experiments in the C6 model of
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injection of ERC would modulate tumor growth. Substan-
tial inhibition of growth was observed by both intravenous
(49% reduction compared to control) and intratumoral
(46% reduction compared to control) groups [61]. These
data suggest that ERC actually act as inhibitory cells for
tumor growth.
The first report of clinical use of ERC involved 4 pa-
tients with multiple sclerosis who received both intra-
thecal and intravenous injections [62]. Patients received
a series of 3–5 injections with a total dose of 16–30 mil-
lion cells. No physical, biochemical, or radiological ab-
normalities were observed at follow up. The patients,
who were treated in 2008, have reported no adverse
events at time of last follow-up (September 2012). The
second published report described a 23 year old male
diagnosed with Duchenne Muscular Dystrophy. On
August 5–14 and November 25–28, 2008 the patient
was treated a total dose of 116 million ERC intramuscu-
larly. No reactions were associated with the stem cell in-
fusion. As of August 1st 2011, no treatment associated
adverse events were noted and the patient was in general
good health [63]. The third clinical report described a
74-year old heart failure patient who received a total of
15 million ERC intravenously over the period of a week.
No adverse events were reported. The last follow-up was
April 1th, 2010 and the patient being in good health [64].
A New delivery technique for stem cells in heart failure:
retrograde administration into the coronary sinus
Historically cardiac cell delivery techniques included
intramyocardial administration (transepicardially or tran-
sendocardially) or antegrade delivery into the coronary ar-
tery. The transepicardial route suffers the drawback of
surgical invasiveness. The transendocardial approach re-
quires complex electromagnetic mapping using systems
such as the NOGA device. Additionally, intramyocardial
administration is not applicable for patients with thinned
myocardium, as this technique may cause perforation.
Antegrade administration into the coronary artery is asso-
ciated with a lower number of cells engrafting [65], as
compared to intramyocardial administration. This is due
to the fact that once the administration balloon is deflated
under the high arterial pressure; the administered cells
dislodge and enter the systemic circulation. Additionally,
administration of cells into the coronary artery has been
shown to increase risk of coronary embolism and ST seg-
ment elevations [66-70].
In humans the coronary sinus drains the anterior left
ventricular wall, which is responsible for the majority of
cardiac contraction. The technique of retrograde delivery
into the coronary sinus has been widely used for the
administration of cardioplegia solution due in part to su-
perior distribution of the solution throughout themyocardium as compared to antegrade delivery [71].
Additionally, the procedure has been demonstrated clin-
ically safe for administration of oxygenated blood during
high risk percutaneous transluminal coronary angio-
plasty [72-74].
The process of retrograde administration into the
coronary sinus involves temporary occlusion of afferent
coronary circulation by means of a balloon catheter
followed by administration against the outflowing blood.
This results in the solution entering the myocardium via
post capillary venules. In contrast to arterioles or capil-
laries, post-capillary venules have the smallest vessel
diameter and conceptually would allow for greatest
transfer of material into the interstitium [75]. Physiolo-
gically, it is known that post-capillary venules are a
major target of immune/inflammatory cell migration
across the endothelium, in part due to expression of ad-
hesion molecules such as ELAM-1 [76], ICAM-1 [77],
CD18 [78], and CD44 [79], and in part because of
biomechanical properties. Given that MSC [80,81],
hematopoietic stem cell [82], and various tissue specific
progenitors [83,84], migrate into tissue using similar
mechanisms/molecules of extravasation as activated leu-
kocytes, it is reasonable to directly deliver cells to “exit
ports” within the coronary microcirculation as compared
to intra-arterially.
Several studies not involving cell therapies have suc-
cessfully utilized retrograde administration in the area of
cardiac regeneration. Boekstegers et al. [85], delivered
adenovirus expressing beta-gal and Luciferase into the
porcine myocardium comparing antegrade delivery into
the coronary artery or retrograde via the anterior cardiac
vein. Significantly elevated expression of the gene in in-
farct tissue in a homogenous manner was observed via
the retrograde method as compared to antegrade. Simi-
lar results were reported by Alino et al. [86], who ob-
served interstitial expression of eGFP in porcine hearts
that were injected in the retrograde manner with naked
DNA. In another study, administration of beta-gal en-
coding plasmid using the retrograde method in pigs
resulted in higher myocardial gene expression in com-
parison to antegrade and intramuscular administration
[87]. This superior level of gene expression in compari-
son to intramyocardial delivery was reproduced in other
studies [88].
The use of retrograde administration has also been
performed successfully for delivery of protein therapeu-
tics. von Degenfeld et al. [89], reported a porcine study
in which retrograde administration of FGF-2 protein was
used to prevent experimentally-induced stenosis. Levels
of radiolabelled FGF-2 in the myocardium of pigs treated
with retrograde were almost twice the levels achieved
using antegrade infusion. Additionally, significant im-
provements in transmural blood flow and regional
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ministered via the retrograde method.
In the area of cell therapy, Suzuki et al. [90] reported ef-
fective distribution of labeled skeletal muscle progenitor
cells via the retrograde method in a rat infarct model. At
28 days increases in cardiac function, decrease in fibrosis,
and retention of administered cells was reported. These
data suggested the feasibility of the retrograde method for
delivery of cells. In a large animal model, George et al.
[91], applied the similar technique in a 90-minute occlu-
sion ischemia porcine model. Retrograde venous adminis-
tration versus antegrade intracoronary administration of
bone marrow mononuclear cells resulted in almost double
the cell retention. These results were subsequently repli-
cated [92].
To date, only one clinical trial has been reported using
the retrograde technique for cell therapy administration.
Tuma et al. treated 14 patients with chronic refractory
angina using autologous bone marrow mononuclear
cells. Cell delivery was successful in all patients with no
arrhythmias, elevated cardiac enzymes or complications
related to the delivery. All but one patient improved by
at least one Canadian Cardiovascular Society class at 2 -
year follow-up compared to baseline. The median base-
line area of ischemic myocardium by SPECT of 38.2%
was reduced to 26.5% at one year and 23.5% at two years
[93].
Thus in terms of gene [84-88,94], protein [89], and cell
delivery [90-93], it appears that retrograde administration
via the coronary sinus is superior in terms of safety and ef-
ficacy to the intracoronary and possibly intramyocardial
routes of administration.
Applying retrograde administration to ERC therapy: the
recover-ERC trial
Medistem has launched the RECOVER-ERC trial in
January 2012 to assess the safety and efficacy of ERCs in
patients with Congestive Heart Failure (CHF) using a
minimally invasive Retrograde Coronary Sinus Delivery.
The study is being conducted under the leadership of
Dr. Leo Bockeria and Dr. Amit Patel at the Bakoulev
Center for Cardiovascular Surgery of Russian Academy
of Medical Science. This study is currently enrolling a
total of 60 ischemic and non-ischemic congestive heart
failure (CHF) patients. Diagnosis of CHF is based on
cardiac function tests, cardiac patient assessment, and
cardiac physician assessments, which include symptom-
atic heart failure in NYHA classification, stage III/IV; left
ventricular ejection fraction of ≤40% and no other car-
diac intervention options likely to improve clinical sta-
tus. The study includes three escalating dose cohorts.
Each consists of 15 treatment (receiving ERCs) patients
and 5 controls (receiving carrier-solution, a placebo).
After 20 patients are enrolled into a lower dose cohort,the dose escalation in the next cohort for the treatment
patients is as follows: 50 million cells (the starting co-
hort), and then 100 million cells (second cohort), and
200 million cells (third cohort).
Safety endpoints are assessed throughout the study
which consist of: Major Cardiac Adverse Events; Adverse
Events/Serious Adverse Events; Elevation of Cardiac En-
zymes post-infusion; Complete blood count; Physical as-
sessment/vital signs; ECG; and ECHO, MRI or SPECT
Abnormalities.
Efficacy endpoints are collected at following time
points and compared to baseline values:
 Cardiac function at 3 month, 6 month and 1 year
 Cardiac remodeling as measured by the change in
LVEDV compared to baseline measured by
echocardiography
 NYHA / CCS Classification at 3 month, 6 month,
and 1 year measured by the change in NYHA from
baseline; and change in CCS from baseline
 Quality of Life Assessment at 3 month, 6 month,
and 1 year measured by the change in Minnesota
Living with Heart Failure Questionnaire (MLHFQ)
from baseline
Subjects who complete the 6 month study duration
will be considered to have completed the study. All sub-
jects should however be followed until completing the
study follow-up at 1 year after treatment or until study
discontinuation for other reasons.
Study update
In June 2012, the Data Safety Monitoring Board com-
pleted 2 month safety review of the first 5 patients
recruited in the study. Based on lack of adverse effects,
the study was allowed to continue enrollment. To date
17 patients have been enrolled in the study, with no Ser-
ious Adverse Events triggering Data Safety Monitoring
Board actions.
Conclusions
Cardiac cell therapy is currently limited by efficacy and
lack of scalable delivery methods. The ERC is a first in
class universal donor stem cell, which possesses superior
angiogenic properties as compared to other clinical stem
cell types. Medistem has initiated a Phase II clinical trial
in CHF combining an “off the shelf” cell drug, with a
practical delivery system. Success of the trial will pos-
ition Medistem to spearhead the development of a true
cardiovascular regenerative therapy.
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